auph stock: Aurinia Pharmaceuticals Guide
AUPH (Aurinia Pharmaceuticals Inc.)
auph stock refers to Aurinia Pharmaceuticals Inc., traded on the Nasdaq under the ticker AUPH. This article provides a compact, neutral reference for investors and readers seeking a clear company overview, product and pipeline summary, market and trading details, governance, regulatory events, analyst coverage, and principal risks. It also points to authoritative sources for live numeric data.
Company overview
Aurinia Pharmaceuticals is a clinical‑stage biopharmaceutical company focused on treatments for autoimmune diseases, notably lupus nephritis. The company is known for the marketed product LUPKYNIS (voclosporin) and ongoing development programs aimed at expanding therapeutic options in autoimmune and renal disease. This profile summarizes the business model, therapeutic focus, headquarters, and mission in concise terms suitable for new readers.
History and corporate development
Aurinia advanced from clinical development into commercialization after securing regulatory approval for its lead therapy. Key milestones include clinical program progress, financing rounds, and the company’s listing on the Nasdaq as AUPH. For milestone dates and detailed corporate filings, consult the company’s investor relations and SEC filings.
Products and research pipeline
The primary marketed product is LUPKYNIS (voclosporin), approved for lupus nephritis. Aurinia’s pipeline includes next‑generation programs such as AUR200 and other candidates targeting immune‑mediated renal conditions. Revenue contribution from LUPKYNIS, trial statuses, and development timelines are available in quarterly reports and investor presentations.
Stock and market information
Trading symbol and exchange: AUPH on the Nasdaq. For live pricing, market capitalization, shares outstanding, float, and volume, consult real‑time market data providers. As of 2026-01-25, according to Nasdaq, AUPH is actively listed and quoted on Nasdaq (check the Nasdaq quote page for up‑to‑date market metrics).
Trading symbols and listings
Aurinia’s primary listing is under the ticker AUPH on the Nasdaq. There are no widely reported cross‑listings on major international stock exchanges; verify current listings in official market pages.
Market data snapshots
Common metrics shown for auph stock include current price, 52‑week high/low, daily volume, average volume, and beta. These values change frequently; authoritative sources to check include Yahoo Finance, MarketWatch, Nasdaq, Morningstar, and YCharts.
Financial performance
Key financials for auph stock—revenues, margins, cash position, and common ratios—are reported quarterly and annually. For complete statements and historical performance, consult the company’s SEC filings (EDGAR) and investor relations materials.
Historical price performance
AUPH has experienced periods of volatility tied to regulatory decisions, trial readouts, and commercial execution for LUPKYNIS. Historical charts and multi‑year performance summaries are available from financial data providers.
Corporate governance and ownership
Information on the board, executive leadership, major institutional holders, and insider ownership trends is disclosed in proxy statements and SEC filings. For recent institutional holdings and insider transactions affecting auph stock, consult filings and trusted market data services.
Regulatory, legal and clinical events
Material regulatory events for auph stock have included FDA approvals and label decisions for LUPKYNIS as well as clinical trial readouts. Any significant litigation or regulatory inquiries are reported in the company’s regulatory filings and press releases.
Analyst coverage and investor sentiment
Analyst reports and price targets for auph stock are published by sell‑side research teams and independent equity analysts. Retail and social sentiment (e.g., StockTwits activity) can provide supplementary color but should not replace primary research.
Risks
Principal risks for auph stock include typical biotech exposures: regulatory approval risk, clinical development failures, commercial execution, competition in autoimmune and renal therapeutics, and market volatility. This is informational and not investment advice.
See also
- Nasdaq listings and market structure
- Basics of biotech investing
- FDA‑approved therapies for lupus nephritis
References and external links
Authoritative sources to verify and obtain live data on auph stock:
- Aurinia Pharmaceuticals — corporate site (Investor Relations)
- Yahoo Finance — AUPH quote & profile
- Nasdaq — AUPH market activity and quotes
- MarketWatch — AUPH quote
- YCharts, Barchart, Morningstar — financial data and analysis pages
- SEC filings (EDGAR) — Aurinia filings and reports
- StockTwits — community sentiment on AUPH
截至 2026-01-25，据 Nasdaq 报道，auph stock 在 Nasdaq 上交易；有关最新市值及日交易量，请查阅上述实时数据提供者。
If you want live market access or to monitor stock‑like products on a trading platform, explore Bitget features and the Bitget Wallet for secure portfolio tracking and alerts.
For further reading and the latest numeric values for auph stock, consult the sources listed above and the company’s most recent SEC filings.
